Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Contact information


david.kerr@ndcls.ox.ac.uk

David Kerr

CBE FMedSci FRCP

Professor of Cancer Medicine

  • Consultant Physician

Genetics and Genomics

In collaboration with Dr Rachel Midgley, Oncology Clinical Trials Office, we have conducted a series of international adjuvant trials of chemotherapy for colorectal cancer. In parallel, we have established a biorepository of tissue and constitutional DNA (n=3500) which has allowed us to collaborate with Ian Tomlinson to generate a number of cancer susceptibility SNPs  and commercial partners  to characterise a prognostic mRNA signature which assists in selection of patients for chemotherapy. We are currently developing biomarkers for the anti-angiogenic agent bevacizumab.